Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065858 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of BufferGel as a Vaginal Contraceptive
A Phase 2 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 975
- Enrollment target
NCT00065858 is a Phase 2 study that has completed, run by Premier Research. The registered enrollment target is 975 participants.
The verdict
NCT00065858, a Phase 2 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 975 participants
- Enrollment target
Study Summary
BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
Interventions
- DRUG BufferGel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065858
The ClinicalTrials.gov registry entry for NCT00065858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BufferGel is the first listed.
NCT00065858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065858 about?
NCT00065858 is a clinical study titled "Effectiveness of BufferGel as a Vaginal Contraceptive". BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
What is the current status of trial NCT00065858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 975 participants. The study started on 2001-09. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00065858?
The interventions under investigation include: BufferGel (DRUG).
Who is sponsoring clinical trial NCT00065858?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.